News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inovio Pharmaceuticals (Formerly Known as Inovio Biomedical Corporation) (INO), TRANSGENE (TRGNY) and Chrontech Pharma AB to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C


4/18/2011 7:24:45 AM

BLUE BELL, Pa., April 18, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. (Euronext Paris: FR0005175080) and ChronTech Pharma AB (CTEC.ST) to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus (HCV) in a phase I clinical study.

It is common to follow an initial "prime" vaccination with a "boost" of the same vaccine to achieve the required level and durability of immune protection. In this collaboration, the strategy is to use different prime and boost vaccines with the goal of obtaining a clinical effect by inducing different immune responses. A Phase I study, to be started later this year, will use ChronTech's ChronVac-C® plasmid DNA vaccine delivered by in vivo electroporation using Inovio's Medpulser® DDS as the "prime" and Transgene's therapeutic vaccine TG4040, a modified vaccinia Ankara (MVA), as the "boost".

DNA based vaccines delivered using electroporation and MVA based vaccines have been separately shown to be safe and immunogenic in clinical studies. The ChronVac-C DNA vaccine delivered by in vivo electroporation using the Medpulser was recently reported to be safe and generate antigen specific immune responses and antiviral effects in a phase I/IIa clinical trial. Rapid virologic responses were seen in 5 out of 7 of the patients receiving a post-vaccination standard of care interferon-ribavirin therapy. TG4040 was itself shown to be safe and immunogenic in a phase I program. Phase II studies in combination with the standard of care are ongoing for both products. In preclinical studies, the novel combination of these DNA and MVA vaccine approaches demonstrated greater immune responses than those observed with the vaccines injected separately.

In the planned phase I clinical study, each company will contribute their respective products and equally share study related costs. The study will enroll 12 treatment-naive patients with chronic hepatitis C at a site in Germany.

Dr. J. Joseph Kim, Inovio's president and CEO, said: "We are pleased to participate in this collaboration to develop a potentially more potent HCV vaccine combination approach and to contribute Inovio's electroporation delivery technology and its well-validated ability to transform the potency of DNA vaccines. We look forward to entering the clinic with this prime-boost approach that has demonstrated much promise in preclinical studies."

"It is our strategy to continuously enhance the efficiency of our technology platforms. We are using the opportunity of this study to explore the prime-boost approach in the context of therapeutic vaccination against HCV," stated Philippe Archinard, Chairman and CEO of Transgene.

"We are very pleased to combine our ChronVac-C vaccine delivered using Inovio's Medpulser with Transgene's TG4040 MVA-based vaccine in a new vaccination regimen. The extensive preclinical studies that have been performed by the companies together with their unique clinical experience has paved the way for this very exciting clinical trial," says Chrontech's CEO Anders Vahlne.

About Chronic Hepatitis C Virus (HCV)

Chronic hepatitis C, with a disease prevalence exceeding 170 million worldwide, is notoriously difficult to treat. Current standard of care (a combination of pegylated interferon alpha and ribavirin) causes serious side effects and cures only 45% of genotype-1 patients. New and more effective drugs are in late stage development, but there remains a need for an effective therapeutic vaccine with lower side effects relative to drug regimens and that is better able to manage the chronic aspects of the disease, prevent its progression to cancer, and reduce long term treatment costs.

In this collaboration, ChronTech's ChronVac-C® DNA vaccine consists of a codon-optimized NS3/4A gene. It is delivered using Inovio's MedPulser® electroporation DNA Delivery System. Inovio's electroporation-based DNA delivery systems dramatically increase cellular uptake of a DNA vaccine and resulting gene expression (i.e. production of the coded protein) and increase immune responses by 100 times or more compared to plasmid DNA delivered without other delivery enhancements. Transgene's TG4040 product candidate is based on an MVA virus carrying and expressing non-structural proteins NS3, NS4 and NS5B of hepatitis C virus.

About Transgene

Transgene, a member of the Institut Merieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases and has five compounds in clinical development: TG4010 and JX-594/TG6006 having completed initial Phase II trials, TG4001 in a Phase IIb trial, TG4040 in a Phase II trial and TG4023 in a Phase I trial. Transgene has concluded strategic agreements for the development of two of its immunotherapy products: an option agreement with Novartis for the development of TG4010 to treat various cancers; and an in-licensing agreement with US-based Jennerex Biotherapeutics, Inc. to develop and market JX-594/TG6006, an oncolytic product. Transgene also has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available at www.transgene.fr.

About ChronTech Pharma

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B for chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections of hepatitis viruses that can lead to cirrhosis and liver cancer. ChronTech has developed a patent-pending new type of needle for a more efficient uptake of DNA vaccines. ChronTech is also a partner in wound healing with its ChronSeal® product and the new platform technology RAS®. ChronTech's shares are listed on First North. For more information, see www.chrontech.se

About MedPulser® DNA Delivery System (DDS)

Inovio's MedPulser DDS is an in vivo electroporation device that delivers and enhances the potency of DNA vaccines. It consists of a pulse generator instrument and handheld applicator with a sterile disposable array. The system delivers electrical pulses that increase cell membrane permeability, resulting in significant cellular uptake of a DNA vaccine and gene expression (i.e. production of the coded antigen). This can increase immune responses by 100 times or more compared to plasmid DNA delivered without other delivery enhancements. The device has been used in a previous ChronVac-C trial and oncology clinical trials.

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include three separate programs in Phase II clinical studies, including VGX-3100 for treating cervical dysplasia and cancer. Other Inovio clinical programs include those for avian flu (preventive) and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010 and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com

Media: Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com

(Logo: http://photos.prnewswire.com/prnh/20110127/LA37605LOGO )

SOURCE Inovio Pharmaceuticals, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES